This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Soren Ostergaard, Ph.D.
Principal Scientist, Research Chemistry 3 at Novo Nordisk A/S


Soren Ostergaard is a principal scientist at Novo Nordisk A/S and has been working with peptide synthesis and technologies for +30 years. He is author or co-author of +85 publications, book chapter and patents/patent applications in the field of therapeutic peptides and proteins, half-life extension, protein-protein interactions, array technologies and combinatorial chemistry to name a few. His current research involves peptide drug design, for the treatment of metabolic disorders and rare diseases e.g., dual or triple acting properties, extended half-life as well as advancing high throughput peptide technologies. He is interacting with academia and serves as supervisor for PhD students. He is representing Novo Nordisk as talent ambassador at career events, giving educational lectures at medicinal chemistry courses at Universities in Denmark as well as serving a PhD assessor.

Agenda Sessions

  • Strategies for Half-Life Extension of Peptide Pharmaceuticals